Stifel analyst Justin Keywood raised the firm’s price target on Knight Therapeutics (KHTRF) to C$7.45 from C$6.25 and keeps a Buy rating on the shares.
Education
About Us
Working with TipRanks
Follow Us
Stifel analyst Justin Keywood raised the firm’s price target on Knight Therapeutics (KHTRF) to C$7.45 from C$6.25 and keeps a Buy rating on the shares.